Why is Concord Biotech falling/rising?

As of 16-Sep, Concord Biotech Ltd's stock price is currently at 1,625.00, reflecting a decrease of 33.0 points or 1.99%. Today's price summary indicates that the stock has underperformed its sector by 2.27% and has experienced a trend reversal, falling after two consecutive days of gains. The stock reached an intraday low of Rs 1613.95, which is a decline of 2.66%. In terms of returns, over the past week, the stock has increased by 2.52%, but it has seen a decline of 0.75% over the past month and a significant drop of 26.47% year-to-date. The company's financial performance has raised concerns, with a recent quarterly profit after tax falling by 52.6% compared to the previous four-quarter average, and net sales hitting a low of Rs 203.99 crore. Additionally, the stock is trading at a premium compared to its peers, indicated by a high Price to Book Value of 9.4, which suggests an expensive valuation.
In the broader market context, while the Sensex has increased by 1.58% over the past week, Concord Biotech's short-term performance has lagged behind this benchmark. The stock's long-term growth prospects appear poor, with a negative return of 21.76% over the past year, and it has underperformed the BSE500 index over multiple time frames. Furthermore, there has been a decline in institutional investor participation, with a decrease of 0.54% in their stake over the previous quarter, which may reflect a lack of confidence in the company's fundamentals. Overall, these factors contribute to the stock's recent downward movement.